The raised guidance and accelerating growth in Surgical and Pharmaceuticals are positive signals. Monitor the Q3 earnings call for updates on the enVista Beyond IOL regulatory submission and any impact from tariffs on the supply chain. The adjusted EPS miss is minor and likely overshadowed by the strong top-line beat and guidance raise.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 29 $16.20entry
- T+1 · 4mo ago +4.88%α +3.20% · $16.99
- T+5 · 3mo ago +3.46%α −2.07% · $16.76
- T+20 · 3mo ago +6.48%α +1.46% · $17.25
- T+60 · 26d ago +7.59%α +2.86% · $17.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Bausch + Lomb reported Q2 2026 revenue of $1.394B (+9% YoY), slightly above consensus of $1.37B, and adjusted EPS of $0.15, slightly below the $0.16 consensus. The company raised its full-year 2026 revenue guidance to $5.440B-$5.540B and Adjusted EBITDA guidance to $1.025B-$1.075B, citing broad-based growth across all segments, particularly Surgical (+19%) and Pharmaceuticals (+15%). The GAAP net loss narrowed to $14M from $62M a year ago, and operating cash flow improved to $153M from $35M. The stock is likely to move modestly higher on the raised guidance and strong operational momentum, though the adjusted EPS miss tempers the upside.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $1.394B, up 9% YoY (8% constant currency), vs consensus $1.37B
- Adjusted EPS of $0.15 vs consensus $0.16 (miss by ~6%)
- GAAP net loss narrowed to $14M from $62M YoY; operating income of $83M vs a loss of $11M
- Full-year 2026 revenue guidance raised to $5.440B-$5.540B (from $5.420B-$5.520B)
- Full-year 2026 Adjusted EBITDA guidance raised to $1.025B-$1.075B (from $1.010B-$1.060B)
- Surgical segment revenue surged 19% (16% constant currency), driven by premium IOLs
- Pharmaceuticals revenue grew 15% (14% constant currency), led by MIEBO and XIIDRA
- Operating cash flow improved to $153M from $35M YoY
- enVista Beyond IOL pivotal study met several co-primary endpoints, though narrowly missed some performance targets
Financial Impact
Revenue beat consensus by ~$24M (1.8%); adjusted EPS missed by $0.01; raised FY guidance by $20M at midpoint
Risk Factors
- enVista Beyond IOL narrowly missed some performance targets, potentially delaying or complicating regulatory submission
- Foreign exchange tailwinds are expected to moderate ($45M vs $50M previously)
- GAAP net loss persists, though narrowing
- Tariff policy remains dynamic and could impact 2026 guidance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001860742-26-000086 |
| Document: blco-20260729.htm | 0001860742-26-000086 |
| Document: 0001860742-26-000086-index-headers.html | 0001860742-26-000086 |
| Document: 0001860742-26-000086-index.html | 0001860742-26-000086 |
| Document: 0001860742-26-000086.txt | 0001860742-26-000086 |
| 8-K Data (Synthetic) | 0001860742-26-000086 |
Track record
24 reports on BLCO
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +16.89% at T+20 after the Oct 1, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $21.14 Now $20.88 −1.23% settles Nov 19
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.03 to $21.37 Now $20.88 +4.24% ▲ +6.69% +7.28% vs SPY
- Oct 29, 202618d ago 144 Neutral 3/10 Entry $20.00 to $19.99 Now $20.88 +4.40% ▼ −0.05% +2.65% vs SPY
- Oct 28, 202619d ago 8-K Neutral 2/10 Entry $20.40 to $19.92 Now $20.88 +2.35% ▼ −2.35% +2.37% vs SPY
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $20.40 to $20.60 Now $20.88 +2.35% ▲ +0.98% +1.69% vs SPY
- Oct 13, 20264w ago 8-K Mixed 6/10 Entry $15.81 to $16.93 Now $20.88 +32.07% ▲ +7.08% +8.24% vs SPY
- Oct 1, 20266w ago Court Ruling Bullish 4/10 Entry $17.11 to $17.30 Now $20.88 +22.03% ▲ +1.11% −0.05% vs SPY
- Sep 28, 20267w ago 144 Neutral 2/10 Entry $16.95 to $17.17 Now $20.88 +23.19% ▲ +1.30% +0.09% vs SPY
- Aug 14, 202613w ago 3 / CLUSTER Neutral 2/10 Entry $17.00 to $17.32 Now $20.88 +22.82% ▲ +1.88% +3.07% vs SPY
- Aug 14, 202613w ago 3 Neutral 2/10 Entry $17.00 to $17.32 Now $20.88 +22.82% ▲ +1.88% +3.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers